Form 4: United Therapeutics CFO Sells Shares Under 10b5-1 Plan

United Therapeutics Corp. CFO and Treasurer James Edgemond reported the sale of 10,000 shares of common stock, acquired through stock option exercises, as part of a pre-arranged 10b5-1 trading plan.

Summary

• James Edgemond, CFO and Treasurer of United Therapeutics Corp., reported transactions on April 13, 2026.
• He exercised stock options to acquire 10,000 shares of common stock at an exercise price of $135.42 per share.
• Following the exercise, Edgemond sold these 10,000 shares under a Rule 10b5-1 trading plan.
• The sales occurred at a weighted average price of $569.61, with individual trades ranging from $569.28 to $579.56.
• These transactions resulted in a net change in beneficial ownership, with 28,876 shares acquired and subsequent sales reducing the total to 18,876 shares directly held after the reported transactions.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the significant sale of shares by a key executive, despite the use of a 10b5-1 plan.

Positives

• The transactions were conducted under a Rule 10b5-1 trading plan, indicating pre-planned and potentially non-insider trading related sales.
• The exercise of stock options suggests that the options were in-the-money, reflecting a potential gain for the executive.

Negatives

• A significant number of shares (10,000) were sold by a key executive, which could be perceived negatively by the market.
• The sale represents a disposal of equity by a high-ranking officer.

Risks

• The sale of a substantial number of shares by an executive could be interpreted as a lack of confidence in future stock performance, although it was executed under a 10b5-1 plan.
• The weighted average sale price of $569.61 indicates a significant gain from the option exercise price of $135.42, but the market may focus on the disposal of shares.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. It is a report of past transactions.

Management Comments

• The exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.
• The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected for various sales executed in multiple trades.

Industry Context

StockSavvy.ai notes that Form 4 filings, particularly those involving sales by executives, are closely watched by investors. The use of a Rule 10b5-1 plan is a standard mechanism for executives to diversify their holdings or meet financial obligations without triggering insider trading concerns, but the volume of shares sold can still influence market perception.

Stakeholder Impact

• Shareholders: May view the sale by a key executive with caution, although the 10b5-1 plan mitigates insider trading concerns.
• Employees: The sale might not have a direct impact, but could influence internal sentiment depending on broader company performance.
• Management: Reinforces the use of established compliance procedures for executive stock transactions.

Next Steps

• The reporting person will continue to hold 18,876 shares of common stock directly.
• Further transactions under the 10b5-1 plan, if any, will be reported in subsequent filings.

Key Dates

Recommendation

The filing reports routine transactions under a pre-established 10b5-1 plan by a key executive. While the sale of shares by an insider can be a point of concern, the structured nature of the plan suggests it is not necessarily a reflection of negative future outlook. Without additional financial or strategic information, a 'hold' recommendation is appropriate, pending further analysis of the company's overall performance and market conditions.

Keywords

Form 4, SEC Filing, United Therapeutics, UTHR, Stock Options, Insider Trading, 10b5-1 Plan, Share Sale, CFO, Executive Compensation